Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories reported steady growth for Q3FY26 and the nine months ended December 31, 2025. Consolidated Q3 revenues were ₹87,268 million, up 4.4% year-on-year but slightly lower sequentially, while 9MFY26 revenues reached ₹260,771 million, an 8% increase from the prior year. Growth was broad-based across India, Europe, Emerging Markets and PSAI, but North America declined mainly due to lower Lenalidomide sales and pricing pressure.
Profitability softened as the business mix shifted. Q3 gross margin fell to 53.6% from 58.7% a year earlier, and EBITDA margin declined to 23.5% from 27.5%. For 9MFY26, EBITDA was ₹66,787 million, down 1% year-on-year, and profit before tax was ₹52,826 million, down 7%, with profit attributable to equity holders essentially flat at ₹40,649 million. Diluted EPS for 9MFY26 was ₹48.78.
The company continues to invest in branded franchises and R&D, while noting one-time costs from changes in Indian labour codes. The balance sheet remains strong, with cash and investments of ₹87,191 million, loans and borrowings of ₹67,732 million, equity of ₹375,756 million, a net cash surplus of ₹30,677 million and an annualised RoCE of 20.4% as of December 31, 2025.
Dr. Reddy’s Laboratories reports stable results for the nine months ended December 31, 2025. Revenues rose to Rs.260,771 million from Rs.240,475 million, driven mainly by the Global Generics segment, which contributed Rs.233,231 million. PSAI added Rs.25,649 million and Others Rs.1,891 million.
Profit for the period was Rs.40,261 million versus Rs.41,373 million a year earlier. Basic EPS for equity holders was Rs.48.83 for the nine months. For the third quarter, revenues reached Rs.87,268 million and profit was Rs.11,896 million.
The balance sheet remains strong with total assets of Rs.562,899 million, equity of Rs.375,756 million and cash and cash equivalents of Rs.18,657 million. Operating cash flow improved to Rs.41,110 million. The company continues to invest in property, plant, equipment and intangibles while managing moderate short-term and lease-related borrowings.